Abstract
The inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to protect various cell types against apoptosis by interacting with the apolipoprotein E receptor 2 (ApoER2). This study investigated the association between PCSK9/ApoER2 signaling and neuronal apoptosis following middle cerebral artery occlusion (MCAO) injury in hyperlipidemic mice. C57BL/6 mice fed a high-fat diet (HFD) were subjected to MCAO, followed by cortical injection of a lentiviral vector harboring short-hairpin RNA (shRNA) targeting PCSK9. Results demonstrated that hyperlipidemia significantly upregulates PCSK9 expression. Ischemia-induced increases in PCSK9 and ApoER2 levels, as well as neuronal apoptosis, were significantly attenuated by PCSK9 shRNA treatment. These findings suggest that the PCSK9/ApoER2 axis is a potential therapeutic target for stroke in hyperlipidemic patients.
Introduction
Ischemic stroke is a leading cause of disability and death worldwide, with hyperlipidemia serving as a major modifiable risk factor. While PCSK9 is primarily known for its role in regulating hepatic low-density lipoprotein (LDL) receptors, its function in the central nervous system is increasingly recognized. Previous research has suggested that PCSK9 may influence neuronal development and cell death, though its interaction with brain receptors like ApoER2 under pathological conditions remains controversial. This study aimed to determine if PCSK9 exacerbates brain damage during stroke in hyperlipidemic conditions and to identify the underlying molecular mechanisms.
Materials and Methods
C57BL/6 mice were fed a high-fat diet (HFD) for six weeks to induce hyperlipidemia, while control mice received a normal-fat diet (NFD). Focal ischemic stroke was simulated using the Middle Cerebral Artery Occlusion (MCAO) model. To inhibit PCSK9, researchers utilized a lentiviral vector carrying shRNA, delivered via stereotaxic injection into the cerebral cortex. Analysis included RT-qPCR for mRNA quantification, Western blotting and Immunohistochemistry (IHC) for protein levels, and TUNEL assays to detect neuronal apoptosis.
Results
Hyperlipidemia and Baseline PCSK9 Elevation
Dietary induction of hyperlipidemia resulted in significantly higher serum LDL-C levels. Notably, HFD mice also exhibited a corresponding increase in PCSK9 mRNA and protein expression within the hippocampus and cortex compared to NFD controls, establishing a baseline of neuro-vulnerability prior to ischemic injury.
The Stroke-PCSK9 Feedback Loop
Ischemic injury further exacerbated the expression of PCSK9 and ApoER2 in the brain. Western blot analysis confirmed that MCAO significantly increased PCSK9 levels in both the hippocampus and cortex of hyperlipidemic mice compared to sham-operated controls.
Neuroprotection via PCSK9 Silencing
Silencing PCSK9 with shRNA successfully reduced ApoER2 protein levels, confirming a functional link between these two pathways during ischemic injury. This molecular intervention led to markedly less histological injury—characterized by reduced vacuolization and neutrophil infiltration—and a significant decrease in the ratio of apoptotic cells in the ischemic penumbra.
Discussion
This study highlights that in a pathological state (stroke combined with high cholesterol), PCSK9 levels are directly correlated with ApoER2 levels. This contrasts with some findings in healthy adult models and suggests that the brain's response to injury in a hyperlipidemic environment is inherently pro-apoptotic. By "knocking down" PCSK9, the researchers were able to downregulate the ApoER2 signaling pathway and provide significant neuroprotection.
Conclusion
The data demonstrate that PCSK9 shRNA-mediated anti-apoptotic effects following MCAO in hyperlipidemic mice are associated with ApoER2 downregulation. This identifies the PCSK9/ApoER2 axis as a potential new therapeutic target for stroke treatment, particularly for patients with comorbid hyperlipidemia.
Summary updated